A Second Look: Revolutionizing Treatment in Hematological Malignancies: Clinical Updates on Obe-cel and AUTO8 Therapies from Autolus Therapeutics

Executed on:Feb 15, 2024 4:00 PM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: Tristar Centennial Medical Center (HCA)Clinical investigator at the Sarah Cannon Treansplant and Cellular Therapy Network in Nashville, TN and Clinical Director for the Adult Transplant Program.
Manages 20 patients a year with Acute Lymphoblastic Leukemia.
Clinical focus on therapy of hematological malignancies and the application of potentially curable cellular therapies; participates in clinical trails in transplant and cellular therapy.

Interview Goal

This interview aims to delve into the latest clinical updates presented by Autolus Therapeutics regarding their innovative CAR T cell therapies, obe-cel and AUTO8. The focus will be on understanding the efficacy, safety, and potential impact of these therapies in treating relapsed/refractory B-cell Acute Lymphoblastic Leukemia (r/r B-ALL), B-cell non-Hodgkin lymphoma (B-NHL), B-cell chronic lymphocytic leukemia (B-CLL), and refractory multiple myeloma.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.